Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15776333 | 0.94 | CNR2 (0.45) | CNR2GSK3AGSK3B | |
| Formic Acid SCHEMBL28228136 | 0.92 | CNR2 (0.48) | CNR2GSK3AGSK3B | |
| SCHEMBL15776679 | 0.79 | CNR2 (0.46) | CNR2 | |
| SCHEMBL28026381 | 0.78 | CNR2 (0.44) | CNR2GSK3B | |
| SCHEMBL19223929 | 0.74 | CNR2 (0.60) | CNR2 | |
| SCHEMBL15791321 | 0.73 | MAPT (0.52) | GSK3AGSK3B | |
| SCHEMBL15733041 | 0.73 | CYP17A1 (0.42) | GSK3AGSK3B | |
| SCHEMBL4397933 | 0.73 | CYP17A1 (0.51) | GSK3AGSK3B | |
| SCHEMBL31754604 | 0.73 | CYP17A1 (0.46) | — | |
| SCHEMBL17316727 | 0.72 | PTGDR2 (0.51) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248803-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248803-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10308659-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308659-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-06-04 | — | — | US | disclosed |
| CN-105121436-B | New pyridine derivate | 豪夫迈·罗氏有限公司 | 2018-07-27 | — | — | CN | disclosed |
| EP-2978755-B1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-01-03 | — | — | EP | disclosed |
| EP-2978755-A1 | NOVEL PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-20160016968-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016968-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016968-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-01-21 | — | — | US | disclosed |
| CN-105121436-A | Novel pyridine derivatives | HOFFMANN LA ROCHE | 2015-12-02 | — | — | CN | disclosed |
| WO-2014154612-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014154612-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308659-B2 | Pyridine derivatives | NDUFS6, NDUFS4, NDUFS8 | CNR2 105/4885GSK3A 2267/4885GSK3B 2049/4885 |
| US-20160016968-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | CNR2 26/4885GSK3A 2745/4885GSK3B 2504/4885 |
| US-20190248803-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | CNR2 26/4885GSK3A 2745/4885GSK3B 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.